Latest Ratios: P/E Ratio -4.1x · EV/EBITDA N/A · ROE -74.4%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $89M | $154M | $204M | $281M | $60M | $105M | $93M | $6M | $6M | $15M | $9M |
| Enterprise Value | $59M | $123M | $194M | $267M | $60M | $65M | $85M | $6M | $6M | $15M | $9M |
| P/E Ratio → | -4.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.47 | 0.79 | 0.96 | 1.84 | 0.50 | 1.13 | 2.50 | 0.48 | 0.76 | 2.96 | 1.75 |
| P/B Ratio | 3.61 | 6.65 | — | 50.50 | — | 4.05 | — | — | 7.73 | 24.01 | — |
| P/FCF | — | — | 34.12 | 3232.66 | — | — | — | 23.62 | — | — | — |
| P/OCF | 10.81 | 18.59 | 11.64 | 31.87 | — | — | — | 23.62 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.64 | 0.91 | 1.75 | 0.51 | 0.70 | 2.28 | 0.46 | 0.77 | 2.96 | 1.75 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 32.46 | 3069.18 | — | — | — | 22.58 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.8% | 79.8% | 88.7% | 87.6% | 84.3% | 80.6% | 76.2% | 79.7% | 76.3% | 70.6% | 62.9% |
| Operating Margin | -4.0% | -4.0% | -7.6% | -9.5% | -36.5% | -58.5% | -155.0% | -23.2% | -24.7% | -21.1% | -22.4% |
| Net Profit Margin | -3.7% | -3.7% | -8.9% | -13.5% | -38.3% | -65.6% | -157.3% | -25.2% | -14.9% | -23.9% | -21.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -2483.1% | -370.0% | -491.9% | -487.2% | — | — | -172.0% | -923.7% | — |
| ROA | -9.9% | -9.9% | -28.8% | -49.0% | -120.5% | -192.3% | -696.1% | -103.5% | -64.0% | -117.4% | -178.9% |
| ROIC | — | — | — | — | — | — | — | — | -200.8% | -514.9% | — |
| ROCE | -37.4% | -37.4% | -89.9% | -161.1% | -406.3% | -408.8% | — | -646.1% | -200.9% | -817.7% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | — | 3.40 | — | 0.07 | — | — | 0.30 | 0.27 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.32 | — | -2.55 | — | -1.53 | — | — | 0.08 | 0.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -1.66 | -163.48 | — | — | — | -1.04 | — | — | — |
| Interest Coverage | -6.48 | -6.48 | -7.40 | -5.71 | -31.10 | -19.31 | -34.67 | -3.80 | -5.80 | -12.72 | -24.16 |
Net cash position: cash ($37M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 0.81 | 1.22 | 0.36 | 1.97 | 0.89 | 0.69 | 1.35 | 1.97 | 0.69 |
| Quick Ratio | 1.18 | 1.18 | 0.76 | 1.15 | 0.24 | 1.90 | 0.80 | 0.45 | 0.49 | 0.87 | 0.55 |
| Cash Ratio | 0.88 | 0.88 | 0.58 | 0.95 | 0.13 | 1.81 | 0.66 | 0.28 | 0.15 | 0.22 | 0.16 |
| Asset Turnover | — | 2.76 | 2.93 | 2.61 | 4.64 | 1.86 | 2.78 | 3.62 | 3.18 | 4.00 | 6.63 |
| Inventory Turnover | 14.17 | 14.17 | 8.60 | 6.85 | 5.04 | 11.13 | 7.01 | 2.66 | 1.93 | 2.10 | 12.14 |
| Days Sales Outstanding | — | 17.50 | 14.12 | 12.63 | 8.69 | 3.85 | 9.77 | 2.85 | 4.34 | 9.26 | 31.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 3.7% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 2.9% | 0.0% | — | — | — | 4.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.9% |
| Total Shareholder Yield | 3.7% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | 0.0% | 0.0% | 0.5% | 0.9% |
| Shares Outstanding | — | $45M | $41M | $34M | $31M | $27M | $14M | $10M | $9M | $9M | $7M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LFMD stock.
LifeMD, Inc.'s current P/E ratio is -4.1x. This places it at the 50th percentile of its historical range.
LifeMD, Inc.'s return on equity (ROE) is -74.4%. The historical average is -298.4%.
Based on historical data, LifeMD, Inc. is trading at a P/E of -4.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
LifeMD, Inc.'s current dividend yield is 3.72%.
LifeMD, Inc. has 79.8% gross margin and -4.0% operating margin.
Key Metrics
Top Statement Risk
Shrinking Equity and Cash Erosion
Metrics are mathematically derived from official filings.
Negative Earnings Leave P/E Unusable
Based on LifeMD's reported trailing figures, the P/E of -10.30 is not meaningful, while the 0.59 P/S and 4.62 P/B suggest the market still prices the equity above its book value despite shrinking revenue and losses.
With trailing earnings negative and no forward P/E available, investors cannot anchor value on earnings multiples and must rely on sales and book value instead. The 4.62 price-to-book ratio appears rich for a company whose equity fell from $23.2M to $8.0M over two quarters and whose revenue declined for consecutive periods. Compared with the peer set, where DOCS trades at 33.17x earnings and 6.81x book, LFMD's low sales multiple reflects weak growth expectations rather than a clear discount, and this gap warrants further investigation.
Gross Margin Strength Obscured by SG&A
As reported in the financial statements, LifeMD's gross margin reached 88.8% in 2026Q2, yet operating margin stayed at -15.1% because SG&A consumed nearly all gross profit.
The high gross margin indicates strong unit economics at the product level, but it does not translate into earning power because operating expenses absorb roughly 99% of gross profit. Operating margin deteriorated from +3.9% in 2025Q1 to -15.1% in 2026Q2, suggesting that cost structure is not scaling down with the revenue decline. Net margin tracks the operating trend closely, so investors should treat the gross margin as an upper bound rather than a proxy for true earnings power.
Returns Decaying as Equity Erodes
Based on LifeMD's reported figures, ROE fell to -61.6% in 2026Q2 from -11.3% a year earlier, while ROA reached -10.9%, indicating that losses are compounding against a shrinking equity base.
The steep decline in ROE is driven partly by the denominator, as equity fell from $23.2M to $8.0M, which mechanically magnifies negative returns. ROIC is not reported for any period, so the capital efficiency picture must be inferred from ROA and ROE, both of which point to value destruction. Peer NUVB shows a similarly negative ROE of -49.7%, but DOCS earns 17.0% ROE, underscoring that LFMD's return profile is structurally weak rather than cyclically depressed.
Current Ratio Slips Below Parity
According to reported financial statements, LifeMD's current ratio fell from 1.25 in 2025Q4 to 0.90 in 2026Q2, with quick ratio at 0.84, placing current liabilities above current assets.
A current ratio below 1.0 combined with a quick ratio of 0.84 suggests limited near-term coverage of short-term obligations without relying on inventory or operating inflows. Cash declined from $36.8M to $25.1M over two quarters, which compresses the liquidity buffer while operating cash flow turned negative. Under a severe stress scenario, the company's ability to meet current liabilities would depend on how quickly receivables convert, a point investors should monitor closely.
Working Capital Metrics Mislead on Cash Cycle
Based on LifeMD's reported figures, the cash conversion cycle of -269 days is driven by DPO of 343 days, which may overstate supplier financing as a source of strength.
A negative cash conversion cycle is usually read as efficiency, but here it reflects an unusually long payables period rather than fast collections, since DSO is only 21 days. Stretching payables to 343 days may indicate reliance on supplier credit that could reverse if vendors tighten terms. Investors should instead examine payables trends alongside operating cash flow, which swung from $8.6M to negative $6.9M, to judge whether the working capital benefit is durable.